MapLight Therapeutics (MPLT) Depreciation and Depletion (2024 - 2025)
MapLight Therapeutics recorded quarterly Depreciation and Depletion of $140000.0 in Q4 2025, up 40.0% quarter-over-quarter from $100000.0 in Q3 2025, and down 30.0% year-over-year from $200000.0 in Q4 2024.
MapLight Therapeutics' Depreciation and Depletion history runs 2 years deep, the most recent figure standing at $140000.0 for Q4 2025.
- In Q4 2025, Depreciation and Depletion fell 30.0% year-over-year to $140000.0; the TTM figure through Dec 2025 stood at $640000.0 (changed N/A YoY), while the FY2025 annual figure was $578000.0, down 17.43% from the prior year.
- Depreciation and Depletion came in at $140000.0 for Q4 2025 at MapLight Therapeutics, up from $100000.0 in the prior quarter.
- In the past five years, Depreciation and Depletion ranged from a high of $200000.0 in Q3 2024 to a low of $100000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - | 140,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 140,000.00 |
| Dec 31, 2025 | 140,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Dec 31, 2024 | 200,000.00 |
| Dec 31, 2024 | 200,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Sep 30, 2024 | 200,000.00 |